Neuropilin Regulation of Angiogenesis, Arteriogenesis, and Vascular Permeability

ALICE PLEIN, ALESSANDRO FANTIN, AND CHRISTIANA RUHRBERG

UCL Institute of Ophthalmology, University College London, London, UK
Address for correspondence: Christiana Ruhrberg, UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK. E-mail: c.ruhrberg@ucl.ac.uk

Received 1 October 2013; accepted 5 February 2014.

ABSTRACT

The formation of the cardiovasculature, consisting of both the heart and blood vessels, is a critical step in embryonic development and relies on three processes termed vasculogenesis, angiogenesis, and vascular remodeling. The transmembrane protein NRP1 is an essential modulator of embryonic angiogenesis with additional roles in vessel remodeling and arteriogenesis. NRP1 also enhances arteriogenesis in adults to alleviate pathological tissue ischemia. However, in certain circumstances, vascular NRP1 signaling can be detrimental, as it may promote cancer by enhancing tumor angiogenesis or contribute to tissue edema by increasing vascular permeability. Understanding the mechanisms of NRP1 signaling is, therefore, of profound importance for the design of therapies aiming to control vascular functions. Previous work has shown that vascular NRP1 can variably serve as a receptor for two secreted glycoproteins, the VEGF-A and SEMA3A, but it also has a poorly understood role as an adhesion receptor. Here, we review current knowledge of NRP1 function during blood vessel growth and homeostasis, with special emphasis on the vascular roles of its multiple ligands and signaling partners.

KEYWORDS: angiogenesis, VEGF, VEGF-A, SEMA3A, neuropilin, NRP1, VEGFR2, endothelial cells, angiogenesis, arteriogenesis, vascular permeability

Abbreviations used: AKT1, RAC-alpha serine/threonine-protein kinase; BCAR1, breast cancer anti-estrogen resistance 1; EEA1, early endosomal antigen 1; EGF, epidermal growth factor; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; NRP, neuropilin; p130CAS, CRK associated substrate; RAB, Ras-related proteins in brain; SEA, serine-glutamic acid-alanine; SEMA3A, semaphorin; SRC, proto-oncogene tyrosine-protein kinase Src; TSAd, T-cell-specific adapter; VEGF-A, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

INTRODUCTION

The cardiovascular system forms during embryonic development to supply growing organs with oxygen and nutrients via a hierarchical blood vessel network, with blood flow generated by the pumping heart. Developmental blood vessel growth occurs through the complementary processes of vasculogenesis to form new vessels from single cell precursors and angiogenesis to expand existing vessels by sprouting growth or intussusception (reviewed in refs [16,64,65]). These processes are accompanied by arteriovenous specification to increase luminal caliber and allow the separation of blood leaving the heart from blood that is returned to it. In addition, endothelial cells acquire organ-specific properties. Thus, endothelial cells in the glomerulus of the kidney become fenestrated to allow passage of solutes, whereas endothelial cells of the brain and retina establish tight junctions to form blood barriers and maintain organ homeostasis (reviewed in refs [64,67]). In most organs, however, intermediate barrier properties are established during embryonic development to enable appropriate serum eflux and extravasation of circulating immune cells during postnatal life.

After birth, angiogenesis continues to support growing tissues, but most blood vessels become quiescent during adulthood. The reactivation of quiescent vessels occurs only under specific circumstances in adults, for example in the cycling uterus and ovary, in the placenta during pregnancy, and in skeletal muscle to support exercise-induced muscle growth (reviewed in refs [16,41,42]). Angiogenesis is also stimulated after injury to promote tissue repair through an increased vascular supply, but this response can be detrimental, for example, in ocular pathologies such as proliferative diabetic retinopathy or the “wet” form of age-related
macular degeneration, in which tissue ischemia leads to the formation of ectopic and leaky blood vessels (reviewed in ref. [16]). Moreover, tumor angiogenesis can promote tumor growth, thus contributing to cancer progression. In such diseases, ne-angiogenesis typically leads to the formation of abnormal vessels with increased vascular permeability. Although vascular permeability is beneficial after acute tissue injury through the delivery of coagulation factors, antibodies, and cytokines, chronic permeability can cause pathological tissue edema.

In this review, we will describe current knowledge of vascular signaling pathways mediated by the transmembrane protein NRP1, a bifunctional receptor for the secreted glycoproteins VEGF-A and SEMA3A that can additionally promote cell-matrix interactions and adhesion (reviewed in [26,71]). We will further discuss the relevance of these NRP1 pathways for the design of novel therapies aimed at normalizing pathological vasculature and stimulating the functional revascularization of ischemic organs.

**DOMAIN STRUCTURE OF NRP1 AND ITS HOMOLOG NRP2**

NRP1 is a single-pass transmembrane glycoprotein of 130 kDa [26] that was originally discovered in the developing frog nervous system as an axonal adhesion protein [82] and subsequently in mammals as a receptor for secreted axon guidance cues of the class 3 semaphorin family such as SEMA3A [38,49]. In addition to binding semaphorins, NRP1 also binds VEGF165, an isoform of the vascular endothelial growth factor VEGF-A that arises through alternative splicing [32,75]. These multiple NRP1 interactions are facilitated by a large extracellular domain of 860 amino acids that is organized into five domains, termed a1, a2, b1, b2, and c (Figure 1A) [26,71]. Whereas the a and b domains bind ligands, the c domain promotes oligomerization.

The class 3 semaphorins bind the a1 and a2 domains of NRP1, and the disruption of this interaction leads to axonal patterning defects without affecting vascular development [36,87]. The b1 and b2 domains mediate binding to the polysaccharide heparin sulfate and VEGF165, and they additionally promote cell adhesion [35,55]; however, the VEGF165 binding sites are distinct from the cell adhesion sites [53,73]. More recently, structural studies of the b1 domain have identified key residues important for ligand interactions in a VEGF165-binding pocket, such as tyrosine (Y) 297 and aspartic acid (D) 320 [43,86,88]. In addition to its extracellular domains, NRP1 has a short, 39 amino acid-long intracellular/cytoplasmic tail that is thought to lack catalytic activity (Figure 1A). However, the C-terminal SEA motif in NRP1’s intracellular domain can recruit synectin, a modulator of endocytic trafficking that is also known as GIPC1 or NIP [4,8,17,28,51,69].

The neuropilin family also includes NRP2, which has roughly 44% amino acid homology with NRP1 and an identical domain structure [14]. NRP2 also binds VEGF-A isoforms and class 3 semaphorins, with preferential binding of VEGF145 and SEMA3F over VEGF165 and SEMA3A, respectively [33]. Although semaphorin signaling through NRP2 plays an important role in neurons, NRP2 is dispensable for blood vascular patterning in mice. NRP2 knockout mice do, however, have mild lymphatic defects [97]. Thus, in contrast to NRP2, NRP1 has pleiotropic and essential roles in the blood vasculature and is, therefore, the focus of this review.

**Figure 1.** NRP1-regulated signaling pathways in endothelial cells in vitro. (A) VEGF165 induces complex formation between NRP1 and VEGFR2 to enhance VEGFR2 signaling in endothelial cells in vitro. In particular, biochemical studies suggested possible roles for NRP1 in the VEGF-mediated induction of pathways involving the activation of ERK, AKT, SRC, P38 MAPK, and p130 CAS. (B) NRP1 regulates integrin-dependent fibronectin remodeling in primary arterial endothelial cells and tumor cells in a mechanism that depends on the NRP1 cytoplasmic domain, but is thought to be VEGFR2 independent.
**NRP1 IN VASCULAR DEVELOPMENT**

During development, NRP1 expression is prominent in growing blood vessels, for example on the endothelial cells of capillaries, arteries, and veins in the postnatal mouse retina and in capillaries in the mouse embryo hindbrain on embryonic day (E) 11.5 [21–23]. The importance of NRP1 for vascular growth was first demonstrated by NRP1 overexpression studies in the mouse embryo, which led to the excessive growth of vessels that were leaky and hemorrhagic [48]. In contrast, loss of NRP1 function in mouse embryos reduces vessel sprouting in organs vascularized by angiogenesis, especially the brain and spinal cord, and it also impairs the remodeling of the heart outflow tract, leading to embryonic lethality by E12.5 in the CD1 mouse background [24,31,47]. In the C57Bl/6 background, NRP1 loss additionally impairs yolk sac vascularization and, therefore, causes death at E10.5 [44], while the JF1 background is compatible with survival up to E14.5 [9,70]. These observations suggest the existence of important, but as yet unidentified genetic modifiers for NRP1 signaling.

In zebrafish, two NRP1 homologs have been identified: nrp1α, whose sequence is phylogenetically more similar to the mammalian gene, and nrp1b, which originates from an early duplication of the NRP1 gene during the evolution of teleost fish [6,57,96]. Knockdown studies with morpholinos for either gene reported impaired intersegmental vessel patterning and resulted in improper arteriovenous connections, suggesting that both nrp1 genes are required for vascular development in fish [52,57,90].

Several studies had raised the possibility that non-endothelial NRP1 regulates angiogenesis. For example, NRP1 is expressed on multiple cell types in an angiogenic setting. Thus, NRP1 is expressed by the tumor cells as well as the tumor vasculature (e.g., [76]), and in the endothelium alongside neural progenitors and tissue macrophages during hindbrain angiogenesis [24]. Moreover, the angiogenic brain defects of endothelial NRP1 knockout mice are milder than those of full knockouts [24]. Using Cre-LoxP technology to create cell type-specific NRP1 mutants in the hindbrain angiogenesis model, we recently examined the dependence of vascular development on endothelial versus nonendothelial NRP1. Surprisingly, we found that, NRP1 was required only on the vascular endothelium for normal angiogenesis, despite its abundant expression by nonendothelial cells [24]. Genetic mosaic experiments further demonstrated that NRP1 is required within the angiogenic endothelium to generate the specialized tip cells that lead vessel sprouts [24].

**NRP1 LIGANDS IN ANGIOGENESIS: VEGF165**

Based on prior biochemical and tissue culture studies, vascular NRP1 functions are widely thought to be mediated by its binding to VEGF165, as this is the VEGF-A isoform with the strongest affinity for NRP1. However, our genetic mouse studies had raised the possibility that NRP1 can also function in angiogenic endothelial cells in a VEGF-independent manner. Most notably, mice expressing only VEGF120 at the expense of NRP1-binding VEGF (Vegfa<sup>120/120</sup>) mice display vascular defects that are different to those of full NRP1 knockout mice; for example, the perisomatic vessels branch normally in E10.5 Nrp1<sup>-/-</sup> null mutants, whereas their branching is reduced in Vegfa<sup>120/120</sup> mutants [68]. Furthermore, the vascular defects in the E12.5 hindbrain differ qualitatively in both types of mutants: Although Nrp1<sup>-/-</sup> null brains show a severe reduction in vessel branching specifically in the subventricular zone, with vessels terminating in bulbous vascular tufts [24,31], Vegfa<sup>120/120</sup> brains show a milder reduction in vessel branching that is accompanied by increased vascular diameter and impaired sprouting both into and within the brain [23,68]. In fact, the vascular defects of Vegfa<sup>120/120</sup> mutants are better explained by the differential affinity of VEGF-A isoforms for the extracellular matrix than their distinct receptor binding properties. Thus, VEGF121 is tightly and VEGF165 partly diffusible, whereas VEGF189 is retained in the matrix, unless released by proteases [61]. These binding properties are thought to allow the isoforms to form chemotactic gradients critical for normal vascular morphogenesis [30,68].

To directly evaluate the importance of VEGF binding to NRP1 for angiogenesis in vivo, we recently examined Nrp1<sup>Y297A/Y297A</sup> mice expressing NRP1 with a point mutation in the VEGF binding pocket [20], as the mutated residue was previously shown to be important for high affinity VEGF binding by NRP1 [40,43]. The Nrp1<sup>Y297A/Y297A</sup> mutants do not show the severe embryonic vascular defects of full or endothelial-specific NRP1 knockout mutants [20]. Hence, VEGF binding to NRP1 is not essential for embryonic angiogenesis, and, therefore, NRP1 must have VEGF-independent roles in angiogenesis that likely synergize with its known role as a VEGFR2 coreceptor.

Although VEGF binding to NRP1 appeared to be largely dispensable for embryonic angiogenesis, the study of newborn and adult Nrp1<sup>Y297A/Y297A</sup> mice revealed essential roles for NRP1 in postnatal angiogenesis and arteriogenesis in the heart and retina, and in pathological neovascularization in a model of neonatal eye disease [20]. In these settings, the vascular phenotypes of Nrp1<sup>Y297A/Y297A</sup> mutants closely resemble the ones of Vegfa<sup>120/120</sup> mice lacking NRP1-binding VEGF, suggesting that NRP1-mediated VEGF-signaling is more important for perinatal and pathological neovascularization than embryonic vascular development. However, because the targeting strategy used to create the Nrp1<sup>Y297A/Y297A</sup> mice inadvertently also reduced NRP1 expression, further studies will be required to unequivocally define the specific contribution of VEGF165 signaling...
through NRP1 to both embryonic and postnatal angiogenesis, as well as pathological neovascularization.

**NRP1 LIGANDS IN ANGIOGENESIS: SEMA3A**

As mentioned above, the extracellular NRP1 domain has distinct VEGF165 and semaphorin binding domains to which these two ligands bind noncompetitively [3]. However, in vivo studies showed that neither SEMA3A nor semaphorin signaling through NRP1 and NRP2 are essential for embryonic angiogenesis in the mouse [36,87]. Moreover, abolishing both SEMA3A and VEGF164 in mice impairs brain vascularization no differently than loss of VEGF164 alone [87]. These observations argue against an obvious role for semaphorin signaling through NRP1 in the vasculature of developing mice. In zebrafish, however, decreasing the levels of either of two SEMA3A orthologs impairs vascular development [74,84]. The exogenous delivery of SEMA3A also disrupts VEGF-A-mediated angiogenesis in the chick choioallantoic membrane assay [1]. It is not yet known why SEMA3A affects angiogenesis in developing fish and chick, but is dispensable for angiogenesis in mouse embryos. In addition, SEMA3A has been reported to also affect pathological angiogenesis in mice. For example, SEMA3A prevents vascular regeneration in a mouse model of oxygen-induced retinopathy [45] and inhibits tumor angiogenesis by eliciting endothelial cell apoptosis and normalizing the pericyte coverage of tumor vessels [12,54]. SEMA3A-induced tumor vessel normalization might be indirectly caused by SEMA3A-mediated recruitment of a subset of NRP1-expressing monocytes that secrete several factors involved in vessel maturation [11,98].

**NRP1 LIGANDS IN ANGIOGENESIS: INTEGRIN LIGANDS IN THE EXTRACELLULAR MATRIX**

In agreement with the original discovery of NRP1 as an adhesion molecule in the nervous system [82], NRP1 was shown to promote endothelial cell attachment to extracellular matrix [59] and to directly interact with integrins in vitro (Figure 1B) [27,85]. Moreover, αvβ3 integrin can negatively regulate VEGF-A-mediated angiogenesis by limiting the interaction of NRP1 with VEGFR2 [66]. The domains that enable NRP1 to modulate adhesion to heterologous, but unidentified proteins on neighboring cells reside in the b1 and b2 domains [73]. It is not yet known whether NRP1-mediated intercellular or cell-matrix adhesion regulates the interaction of blood vessels with their environment during angiogenesis in vivo. Nevertheless, NRP1-mediated extracellular matrix remodeling takes place in primary arterial endothelial cells and tumor cells and appears to be mediated by the NRP1 cytoplasmic tail without requirement for VEGFR2 activation by VEGF [85,95] (Figure 1B).

**MECHANISM OF NRP1 SIGNAL TRANSDUCTION IN THE VASCULATURE: ASSOCIATION WITH VEGFR2**

The cytoplasmic tail of NRP1 lacks any known catalytic activity, suggesting that NRP1 transduces signals in the vasculature through a coreceptor. This would be analogous to how NRP1 conveys semaphorin signals in the nervous system, where A-type plexins function as a NRP1-coreceptor and signal transducer [60]. Candidates for NRP1 signal transduction in endothelial cells are the VEGF-A receptor tyrosine kinases VEGFR1 (FLT1) and VEGFR2 (KDR), as both have been shown to interact with NRP1 in vitro, and because NRP1 increases VEGFR2 phosphorylation [25,34,77,93]. In fact, the most widely accepted model of NRP1 function in angiogenesis postulates that it forms a VEGF165-dependent complex with VEGFR2 to enhance the activation of a wide variety of intracellular signal transduction pathways, including those that involve (ERK) 1 and 2 (MAPK1 and MAPK3), the serine/threonine protein kinase AKT1, the avian sarcoma viral oncogene homolog SRC, p38 MAPK (MAPK14) and the P130 CRK-associated substrate (CAS), also known as breast cancer anti-estrogen resistance 1 (BCAR1) (Figure 1A) [1,5,19,46,51,89].

The VEGF165-mediated interaction between NRP1 and VEGFR2 may occur in cis, if both receptors are coexpressed on the same endothelial cell, or in trans, if VEGFR2 is expressed by an endothelial cell and NRP1 by an adjacent endothelial or nonendothelial cell. Thus, it has been proposed that endothelial VEGFR2 may interact with tumor NRP1 in trans [76]. However, the significance of trans interactions has not yet been established for tumor angiogenesis, nor is it known if trans interactions take place between endothelial and mural cells in the dorsal aorta [62,94]. We have recently shown that a trans interaction between nonendothelial NRP1 and vascular endothelium is dispensable for angiogenesis in the developing brain, where endothelial NRP1 alone is essential for normal vessel growth [24,36]. Thus, the ablation of NRP1 from the neural progenitors that secrete VEGF-A for vessel sprouting or from the macrophages that promote vascular anastomosis did not compromise brain angiogenesis [24] (see above).

Recent in vitro studies suggest that NRP1-VEGFR2 complex formation requires the C-terminal SEA motif in the NRP1 cytoplasmic tail and its intracellular binding partner synectin [63]. This complex is thought to promote ligand-dependent endocytosis of VEGFR2-NRP1 complexes in cultured endothelial cells [69]. Overexpression studies with VEGF receptors and fluorophore-linked RAB proteins in porcine aortic endothelial cells, which lack endogenous
VEGF receptor expression, further suggested that the synectin-binding motif of NRP1 promotes sequential, NRP1-mediated VEGF2 recycling through specific subsets of RAB-vesicles after VEGF165 stimulation [4]. The latter study concluded that NRP1-mediated VEGF2 recycling controls signaling output from VEGF-A-activated VEGFR2 complexes [4].

Although NRP1-mediated VEGFR2 trafficking was initially hypothesized to promote angiogenesis (e.g., ref [4]), the analysis of mice lacking the cytoplasmic tail of NRP1 showed that this domain is dispensable for developmental angiogenesis in the mouse [22], which involves blood vessel sprouting, migration, and vascular anastomosis. In contrast, the NRP1 cytoplasmic tail is essential for efficient angiogenesis, a process that involves luminal vessel growth [51]. Thus, loss of the NRP1 cytoplasmic tail impairs arterial morphogenesis during development and in adult hindlimb ischemia, similar to the loss of synectin [15], which serves as an adaptor to link VEGFR2 to myosin VI motors for endocytic trafficking into EEA1+ endosomes [50]. Mechanistically, these studies suggest a model in which the cytoplasmic tail of NRP1 mediates VEGF165-stimulated VEGFR2 cotrafficking with NRP1 via a synectin/myosin VI complex into EEA1+ endosomes, where VEGFR2 is protected from dephosphorylation by the phosphatase PTP1b to maximize the phosphorylation of ERK1/2 [51], a previously identified target of NRP1-dependent VEGF2 signal transduction (Figure 1A) [5].

VEGFR2-INDEPENDENT NRP1 SIGNALING IN ENDOTHELIAL CELLS

Several tissue culture studies raised the possibility that NRP1 can promote endothelial migration and extracellular matrix remodeling independently of VEGFR2. First, fusion of the extracellular domain of the EGF receptor to the transmembrane and cytoplasmic domains of NRP1 creates a chimeric receptor that promotes endothelial cell migration in response to EGF, independently of VEGFR2 [91]. Second, NRP1 is required for the VEGF-induced migration of primary venous endothelial cells via activation of p130CAS, and overexpression studies raise the possibility that this may occur independently of VEGFR2 phosphorylation [19]. Third, NRP1 promotes adhesion of endothelial cells to low concentrations of extracellular matrix component and integrin ligand fibronectin, independently of VEGF2 [59] in a mechanism that involves the NRP1 cytoplasmic tail [85]. Because the cytoplasmic domain of NRP1 is dispensable for developmental angiogenesis [22], these tissue culture studies may have identified signaling pathways that are selectively important for endothelial cell migration in specific circumstances, for example in pathological situations (although in vivo evidence for this suggestion is still lacking). In contrast to mice, zebrafish show defective vascular development in the absence of the SEA motif in the NRP1 cytoplasmic domain [90] or its interactor synectin [15]. These species differences are reminiscent of the selective importance of SEMA3A for zebrafish, but not mouse intersomitic vessel development (see above). In summary, it is clear that NRP1 plays an essential role in angiogenesis, but conflicting data obtained in tissue culture, zebrafish, and mouse models need to be resolved to fully understand the signaling mechanism of NRP1 during angiogenesis and other vascular functions in vivo.

ROLE FOR NRP1 IN ARTERIOVENOUS PATTERNING

NRP2 is enriched in the venous and NRP1 in the arterial parts of vascular networks in chick, mouse and zebrafish [22,39,44,57]. Although Nrp2-null mice develop to term without obvious arteriovenous or other type of blood vascular defects [97], specific arterial markers are missing from arteries and arteries in full and endothelial-specific Nrp1 knockouts [44,58]. The arterial differentiation defects observed in limb skin are thought to be due to defective VEGF-A signaling [58]. In agreement, both the loss of NRP1 binding VEGF-A isoforms and, inversely, the loss of VEGF-A binding to NRP1 impair arterial development in the retina and the heart in a similar manner [10,80]. Endothelial NRP1 deficiency also precludes normal remodeling of the arterial pole of the developing heart from a common outflow tract into the pulmonary artery and aorta [36]. This observation has been proposed to be due to defective VEGF-A binding to NRP1 on outflow tract endothelium [36], agreeing with the observation that Vegfa120/120 mice lacking NRP1-binding VEGF165 have similar defects [79]. However, loss of VEGF-A binding to NRP1 does not affect embryonic viability, which depends on a properly remodeled outflow tract [20], and mice lacking semaphorin signaling through NRP1 also have defective outflow tract remodeling [36]. Accordingly, further work is needed to define the specific roles of NRP1 in endothelial cells and other cell types that interact with the endothelium during outflow tract remodeling, such as neural crest cells.

Despite its essential role in arterial morphogenesis, the NRP1 cytoplasmic domain is dispensable for NRP1-mediated arterial differentiation in the retina; instead, the NRP1 cytoplasmic domain promotes the spatial segregation of arteries and veins to regulate arteriovenous patterning in this tissue. Specifically, retinal arteries and veins cross over each other in the Nrp1−/− embryos mutants at an abnormally high frequency [22]. In humans, similar arteriovenous crossings, in the presence of additional systemic factors, are thought to increase the likelihood of developing branch retinal vein occlusion, in which compression of the vein by the artery...
disrupts retinal blood flow [7,92]. Arteriovenous crossings have also been identified in the retina of mice with haploinsufficient expression of VEGF-A in neural progenitors [37], suggesting that NRP1 conveys VEGF-A signals through its cytoplasmic domain to implement the spatial separation of arteries and veins in the retina. However, is not yet known if this process requires NRP1 expression in endothelial or mural cells, as the latter are also known to express NRP1 in certain situations [62,94].

**NRP1 IN VASCULAR PERMEABILITY**

Although VEGF-A is best known as an angiogenic growth factor, it was first described as a vascular permeability factor, because it disrupts endothelial barrier function in tumors and increases the leakage of serum proteins and therefore interstitial pressure [72]. In an inflammatory setting, the effect of VEGF-A on permeability is beneficial, because it enables the delivery of clotting factors and antibodies, but in chronic conditions such as age-related macular degeneration it is detrimental, because tissue swelling impairs vision. Mechanistically, VEGF-A-mediated VEGFR2 activation induces the internalization of VE-cadherin from adherens junctions [18] and increases paracellular permeability in a SRC- and T-cell-specific adapter (TSAD) (SH2D2A)-dependent mechanism [29,81]. Supporting an additional role of NRP1 in VEGF-mediated vascular permeability, mice that overexpress soluble NRP1 in the skin show reduced leakage in response to VEGF165 in the Miles assay, a technique that measures vascular leak in the skin [56]. Moreover, antibody neutralization of NRP1 attenuates VEGF165-induced vascular leakage in lung tissue [5]. Interestingly, C-end rule peptides with a C-terminal arginine residue in a configuration similar to that of VEGF-A bind NRP1 to induce vascular permeability [83], and this property may be exploited to enhance tumor penetration of chemotherapeutic drugs [2].

It is not yet clear how NRP1 and VEGFR2 cooperate to regulate vascular permeability. On the one hand, NRP1 and VEGFR2 need to be coexpressed in porcine aortic endothelial cells to restore the VEGF165-induced decrease in transendothelial electrical resistance, an inverse indicator of permeability [5]. On the other hand, some experiments suggest that NRP1 promotes permeability independently of VEGFR2. First, blocking VEGFR2 in pulmonary artery endothelial cells does not prevent the VEGF165-mediated decrease in transendothelial electrical resistance, while blocking NRP1 does [5]. Second, a mutant form of VEGF165 lacking the ability to bind VEGFR2, but predicted to still bind NRP1, can also induce vascular permeability [78].

In addition to binding VEGF165, NRP1 can also bind SEMA3A to induce permeability in the Miles assay that measures vascular permeability in the skin [1]. In agreement, a recent study revealed that SEMA3A is induced in the neural retina of diabetic humans and mice, where it promotes vascular leakage in a NRP1-dependent way [13]. SEMA3A binding to NRP1 may, therefore, provide a therapeutic target in diabetic retinopathy. It has not yet been investigated if this pathway is also involved in other diseases in which elevated vascular permeability is a contributing factor, such as cancer, stroke, and other eye diseases. Moreover, further studies are required to better discern the precise downstream mechanisms that enable the VEGF-A isoforms and semaphorins to regulate vascular permeability in vivo.

**PERSPECTIVE**

Due to its pleiotropic roles in angiogenesis, arteriogenesis, and vascular permeability, NRP1 provides a promising molecular target for diseases involving aberrant vascular growth or excessive vascular leak. In particular, a better understanding of NRP1 signaling may enable the design of therapies that can revascularize ischemic tissues via VEGF-A-stimulated angiogenesis and arteriogenesis, but avoid induction of excess vascular leak.

**ACKNOWLEDGMENTS**

C.R. and A.F. are supported by a Wellcome Trust Investigator Award (095623/Z/11/Z). A.P. is supported by a PhD studentship from the British Heart Foundation (FS/10/54/28680).

**REFERENCES**

1. Acevedo LM, Barillas S, Weis SM, Gothert JR, Cheresh DA. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. *Blood* 111: 2674–2680, 2008.

2. Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Tessler T, Bordignon C, Traversari C, Rizzardi G-P, Rusolati E. De novo design of a tumor-penetrating peptide. *Cancer Res* 73: 804–812, 2013.

3. Appleton BA, Wu P, Maloney J, Yin J, Liang W-C, Stawicki S, Mortara K, Bowman KK, Elliott JM, Desmarais W, Bazan JF, Bagri A, Tesser-Lavigne M, Koch AW, Wu Y, Watts RJ, Wiesmann C. Structural studies of neuropilin-antibody complexes provide insights into semaphorin and VEGF binding. *EMBO J* 26: 4902–4912, 2007.

4. Ballmer-Hofer K, Andersson AE, Ratcliffe JR, Cheresh DA. Semaphorin 3A suppresses VEGF-A-mediated vascular permeability, mice that overexpress soluble NRP1 in the skin show reduced leakage in response to VEGF165 in the Miles assay, a technique that measures vascular leak in the skin [1]. In agreement, a recent study revealed that SEMA3A is induced in the neural retina of diabetic humans and mice, where it promotes vascular leakage in a NRP1-dependent way [13]. SEMA3A binding to NRP1 may, therefore, provide a therapeutic target in diabetic retinopathy. It has not yet been investigated if this pathway is also involved in other diseases in which elevated vascular permeability is a contributing factor, such as cancer, stroke, and other eye diseases. Moreover, further studies are required to better discern the precise downstream mechanisms that enable the VEGF-A isoforms and semaphorins to regulate vascular permeability in vivo.

**ACKNOWLEDGMENTS**

C.R. and A.F. are supported by a Wellcome Trust Investigator Award (095623/Z/11/Z). A.P. is supported by a PhD studentship from the British Heart Foundation (FS/10/54/28680).
genes in developing zebrafish. Gene Expr Patterns 4: 361–370, 2004.
7. Cahill MT, Fekrat S. Arteriovenous sheath-otomy for branch retinal vein occlusion. Ophthalmol Clin North Am 15: 417–422, 2002.
8. Cai H, Reed RR. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J Neurosci 19: 6519–6527, 1999.
9. Cariboni A, Davidson K, Dozio E, Memi F, Schwartz O, Stossi F, Parmaleras JG, Ruehrberg C. VEGF signalling controls GMR neuron survival via NRP1 independently of KDR and blood vessels. Development 138: 3723–3733, 2011.
10. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmann K, Cornelissen I, Ehrler E, Kakkar VV, Stalmins I, Mattot V, Perriard JC, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D’Amore PA, Shima DT. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Circulation 118: 12340–12345, 2008.
11. Cahill MT, Fekrat S. Arteriovenous sheath-otomy for branch retinal vein occlusion. Ophthalmol Clin North Am 15: 417–422, 2002.
12. Cappuccio F, LoVullo C, Battaglia G, Bruschi S, Tosti A, Marini A, Gherri C, Bussolino F, Giaccà M. Neuropilin-1 identifies a subset of bone marrow Gr1+ monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer Res 72: 6371–6381, 2012.
13. Capano A, Tettoreta N, Menard C, Lapalme E, Patel C, Sitara N, Beaufon F, Leboeuf D, de Guire V, Binet F, Dejda A, Rezende FA, Miloudi K, Saipah P. Neuron-derived semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler Thromb Vasc Biol 32: 663–670, 2012.
14. Carpen A, Tettoreta N, Menard C, Lapalme E, Patel C, Sitara N, Beaufon F, Leboeuf D, de Guire V, Binet F, Dejda A, Rezende FA, Miloudi K, Saipah P. Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell Metab 18: 505–518, 2013.
15. Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 19: 547–559, 1997.
16. Chittenden TW, Claes F, Lanahan AA, Autiero M, Palac RT, Tkachenko EV, Elfenbein A, Ruiz de Almodovar C, Dedkov E, Tomane R, Li W, Westmore M, Singh JP, Horowitz A, Mulligan-Kehoe MJ, Moodie KL, Zhuang ZW, Carmeliet P, Simons M. Selective regulation of arterial branching morphogenesis by synectin. Dev Cell 10: 783–795, 2006.
17. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 27: 563–584, 2011.
18. De Vries L, Lou X, Zhao G, Zheng B, Farquhar MG. GFpC, a PDZ domain containing protein, interacts specifically with the C terminus of RGS-Gaip. Proc Natl Acad Sci USA 95: 12340–12345, 1998.
19. Dejana E, Orsenigo L, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 121: 2115–2122, 2008.
20. Evans IM, Yamaji M, Britton G, Pellet-Many E, Dejana E, Filippi M, Serini G, Lampugnani MG. Cell adhesion molecules and inhibit tumor growth. J Biol Chem 283: 27478–27488, 2008.
21. Evans IM, Yamaji M, Britton G, Pellet-Many E and Sema IV but not Sema III. Neuron 19: 547–559, 1997.
22. Fantin A, Herzog B, Mahmoud M, Yamaji M, Plein A, Denti L, Ruehrberg C, Zachary I. Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis. Development 141: 556–562, 2014.
23. Fantin A, Plein A, Ruehrberg C. Neuropilin signalling in vascular development and pathology. Curr Opin Cell Biol 1: 125–132, 2012.
24. Fantin A, Schwarz Q, Davidson K, Nemando EM, Denti L, Ruehrberg C. The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins. Development 138: 4185–4191, 2011.
25. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Pykhozhii S, Peri F, Wilson SW, Ruehrberg C. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 116: 829–840, 2010.
26. Fantin A, Vieira JM, Plein A, Denti L, Fruttiger M, Pollard JW, Ruehrberg C. NRP1 acts cell autonomously in endothelial tip cell induction. Blood 116: 829–840, 2010.
27. Fukasawa M, Matsushita A, Korc M. Neuropilin-1 interacts with integrin β1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biol Ther 6: 1173–1180, 2007.
28. Gao Y, Li M, Chen W, Simons M, Syntich, syndecan-4 cytoplasmic domain binding PDZ protein, inhibits cell migration. J Cell Physiol 184: 373–379, 2000.
29. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8: 1223–1234, 2006.
30. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314: 15–23, 2003.
31. Gerhardt H, Ruehrberg C, Abramsson A, Fujisawa H, Shima D, Betsholtz C. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev Dyn 231: 503–509, 2004.
32. Gitay-Goren H, Cohen T, Tessler S, Soker S, Gengrinovitch S, Rockwell P, Klagsbrun M, Levi RZ, Neufeld G. Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem 271: 5519–5523, 1996.
33. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (v-EGF) forms VEGF-145 and VEGF-165 [ correction]. J Biol Chem 279: 29922, 2004.
34. Gluzman-Poltorak Z, Cohen T, Shibuya M, Neufeld G. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem 276: 18688–18694, 2001.
35. Gu C, Limberg BJ, Whitaker GB, Perman B, Leahey DJ, Rosenbaum JS, Ginty DD, Kolodkin AL. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem 277: 18069–18076, 2002.
36. Gu C, Rodriguez ER, Reimert DV, Shu T, Fritsch B, Richards LJ, Kolodkin AL, Ginty DD. Neuropilin-1 conveys semaphorin and VEGF signalling during neural and cardiovascular development. Dev Cell 5: 45–57, 2003.
37. Haigh JJ, Morelli PI, Gerhardt H, Haigh K, Tomsen E, Darmet A, Miquero L, Muhliner U, Klein R, Ferrara N, Wagner EF, Betsholtz C, Nagy A. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signalling. Dev Biol 262: 225–241, 2003.
38. Haigh JJ, Morelli PI, Gerhardt H, Haigh K, Tomsen E, Darmet A, Miquero L, Muhliner U, Klein R, Ferrara N, Wagner EF, Betsholtz C, Nagy A. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signalling. Dev Biol 262: 225–241, 2003.
39. Herzog Y, Kalcheim C, Kahane N, Reshef R, Neufeld G. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev 109: 115–119, 2001.
40. Herzog B, Pellet-Many C, Britton G, Hartzoulakis B, Zachary IC. VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Mol Biol Cell 22: 2766–2776, 2011.
41. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruin EA. Vascular endothelial growth factor and angiogenesis. Pharmaco 56: 549–580, 2004.
42. Hudlicka O, Brown M, Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol Rev 72: 369–417, 1992.
43. Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, Winfield N, Ellard K, Aqil R, Lynch R, Chapman C, Hartzoulakis B, Nally J, Stewart M, Cheng L, Menon M, Tickner M, Djordjevic S, Driscoll PC, Zachary IC, Selwood GM, Kondoh H, Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mouse embryos. J Cell Biol 126: 4895–4902, 1999.
44. Kawamura H, U X, Goishi K, van Meeteren LA, Jakobsen L, Cebe-Suarez S, Shimizu A, Edholm D, Ballmer-Hofer K, Kjellen L, Klagsbrun M, Claesson-Welsh L. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112: 3638–3649, 2008.
45. Kawamura H, U X, Goishi K, van Meeteren LA, Jakobsen L, Cebe-Suarez S, Shimizu A, Edholm D, Ballmer-Hofer K, Kjellen L, Klagsbrun M, Claesson-Welsh L. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112: 3638–3649, 2008.
46. Kawamura H, U X, Goishi K, van Meeteren LA, Jakobsen L, Cebe-Suarez S, Shimizu A, Edholm D, Ballmer-Hofer K, Kjellen L, Klagsbrun M, Claesson-Welsh L. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112: 3638–3649, 2008.
47. Kawamura H, U X, Goishi K, van Meeteren LA, Jakobsen L, Cebe-Suarez S, Shimizu A, Edholm D, Ballmer-Hofer K, Kjellen L, Klagsbrun M, Claesson-Welsh L. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112: 3638–3649, 2008.
48. Kawamura H, U X, Goishi K, van Meeteren LA, Jakobsen L, Cebe-Suarez S, Shimizu A, Edholm D, Ballmer-Hofer K, Kjellen L, Klagsbrun M, Claesson-Welsh L. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112: 3638–3649, 2008.
49. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger R, Ginty DD. Neuropilin is a semaphorin III receptor. Cell 90: 753–767, 1997.
50. Lanahan AA, Hermons K, Claes F, Kerley-Hamilton JS, Zhuang ZW, Giordano FJ, Carmeliet P, Simons M. VEGF receptor 2 endo- cytosis is regulated by semaphorin D2. Dev Cell 18: 713–724, 2010.
51. Lanahan A, Zhang X, Fantin A, Zhuang Z, Rivera-Molina F, Speichinger K, Praht C, Zhang J, Wang Y, Davis G, Toomre D, Ruhrberg C, Simons M. The neuropilin 1 cytoplasmic domain is required for VEGF-A-dependent angiogenesis. Dev Cell 25: 156–168, 2013.
52. Lee P, Goishi K, Davidson AJ, Mannix R, Zon L, Klagsbrun M. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc Natl Acad Sci USA 99: 10470–10475, 2002.
53. Lee CC, Kreusch A, McMullan D, Ng K, Spraggan G. Crystal structure of the human neuropilin-1 b1 domain. Structure 11: 99–108, 2003.
54. Maione F, Molla F, Meda C, Latin R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraud E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 119: 3356–3372, 2009.
55. Mamuluk R, Giechman Z, Kutcher ME, Gasunas N, Gallagher J, Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor, and tumor growth factor-2, and heparin via its b1b2 domain. J Biol Chem 277: 24818–24825, 2002.
56. Mamuluk R, Klagsbrun M, Detmar M, Bie- lenberg DR. Soluble neuropilin targeted to tumor vasculature in transgenic mouse models. J Cell Biol 126: 4895–4902, 2000.
57. Martyn U, Schulte-Merker S. Zebrafish morphogenesis. Nat Rev Genet 56: 549–553, 2005.
58. Martyn U, Schulte-Merker S. Zebrafish morphogenesis. Nat Rev Genet 56: 549–553, 2005.
59. Martyn U, Schulte-Merker S. Zebrafish morphogenesis. Nat Rev Genet 56: 549–553, 2005.
60. Nakamura F, Tanaka M, Takahashi T, Kalb RG, Strittmatter SM. Neuropilin-1 extracellular domains mediate semaphorin Dril-
Neuropilin 1 in the Vasculature

73. Shimizu M, Murakami Y, Sato F, Fujisawa H. Determination of cell adhesion sites of neuropilin-1. J Cell Biol 148: 1283–1293, 2000.

74. Shoji W, Isogai S, Sato-Maeda M, Obinata M, Kuwada JY. Semaphorin3a1 regulates angioblast migration and vascular development in zebrafish embryos. Development 130: 3227–3236, 2003.

75. Soker S, Fidder H, Neufeld G, Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 271: 5761–5767, 1996.

76. Soker S, Miao HQ, Nomi M, Takashima S. Semaphorin3a1 regulates neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 106: 16157–16162, 2009.

77. Torres-Vazquez J, Gitter AD, Fraser SD, Berk PA, Cao S, Alitalo K. Neuropilin-1 modulates p53/caspases selective requirements for NRP1 ligands during neurovascular patterning. Development 134: 1833–1843, 2007.

81. Sun Z, Li X, Massena S, Kutschera S, Padhan N, Gualandri L, Sundvold-Gjerstad V, Gustafsson K, Choy WW, Zang G, Quach M, Jansson L, Phillipson M, Abid MR, Sparkland A, Claesson-Welsh L. VEG-FR2 induces c-Src signaling and vascular permeability in vivo via the adapter protein TSD. J Exp Med 209: 1363–1377, 2012.

82. Takagi S, Kasuya Y, Shimizu M, Matsuura T, Tsuboi M, Kawakami A, Fujisawa H. Expression of a cell adhesion molecule, neuropilin, in the developing chick nervous system. Dev Biol 170: 207–222, 1995.

83. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. J Biol Chem 281: 28484–28492, 1999.

84. Stacke SA, Vital A, Caesar C, Domagala T, Groenen LC, Nice E, Achen MG, Wilks AF. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J Biol Chem 274: 34884–34892, 1999.

85. Stalman I, Lambrechts D, De Smet F, Jansen S, Wang J, Maity S, Kneer P, von der Ohe M, Swillen A, Maes C, Gewillig M, Molin DG, Hellings P, Boetel T, Haardt M, Plaisance S, Compernolle V, Dewerchin M, Plaisance S, Vliegen K, Eeman A, Bettinger R, Serini G. Neuropilin-1/GIPC1 signaling guides patterning of the developing vasculature. J Exp Med 197: 1283–1293, 2004.

86. Valdemarini D, Caswell PT, Anderson KI, Schwartz M, Newman JC, Humphries MJ, Bussolino F, Serini G. Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells. PLoS Biol 7: e25, 2009.

87. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci USA 104: 6152–6157, 2007.

88. Vieira JM, Schwarz Q, Ruhberg C. Selective requirements for NRP1 ligands during neurovascular patterning. Dev Growth Diff 53: 1283–1292, 2007.

89. von Wrónski MA, Raju N, Pillai R, Bogdan NJ, Marinelli ER, Nanjappa P, Ramalingam K, Arunachalam T, Eaton S, Linder KE, Yan F, Pochon S, Tweddle MF, Nunn AD. Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor. J Biol Chem 281: 5702–5710, 2006.

90. Wang L, Mukhopadhyay D, Xu X. C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB J 28: 1513–1515, 2006.

91. Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem 278: 48848–48860, 2003.

92. Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol 109: 298–302, 1990.

93. Whitaker GB, Limberg BJ, Rosenbaum JS. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF (165) and VEGF (121). J Biol Chem 276: 25520–25531, 2001.

94. Yang H, Nan B, Yan S, Li M, Yao Q, Chen C. C-reactive protein decreases expression of VEGF receptors and neuropilins and inhibits VEGF165-induced cell proliferation in human endothelial cells. Biochem Biophys Res Commun 333: 1003–1010, 2005.

95. Yasung U, Cao S, Shergill U, Jagavelu K, Geng Z, Yin M, de Assuncao TM, Cao Y, Szabolcs A, Thorgersson S, Schwartz M, Yang JD, Ehman R, Roberts L, Mukhopadhyay D, Shah VH. Neuropilin-1 stimulates tumor growth by increasing fibroconnectin fibril assembly in the tumor microenvironment. Cancer Res 72: 4047–4059, 2012.

96. Yu HH, Housart C, Moens CB. Cloning and embryonic expression of zebrafish neuropilin genes. Gene Expr Patterns 4: 371–378, 2004.

97. Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, Alitalo K, Eichmann A. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129: 4797–4806, 2002.

98. Zacchigna S, Pattarini L, Zentilin L, Moimas S, Carrer A, Sinigaglia M, Arsic N, Tafuro S, Sinagra G, Giacca M. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. J Clin Invest 118: 2062–2075, 2008.